Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients.
Deeks
Steven G
SG
University of California, San Francisco General Hospital, San Francisco, CA 94110, USA. sdeeks@php.ucsf.edu
D000818:Animals; D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D065100:CCR5 Receptor Antagonists; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D006678:HIV / Q000254:growth & development; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D051379:Mice; D016032:Randomized Controlled Trials as Topic; D019713:Receptors, CCR5 / Q000627:therapeutic use; D014779:Virus Replication / Q000187:drug effects
D044966:Anti-Retroviral Agents; D065100:CCR5 Receptor Antagonists; D019713:Receptors, CCR5